The Recall Desk
Agency classClass IIOur severity:SevereFDA (Drugs)·D-0166-2027·Announced 2026-11-11

Hikma Recalls Ciprofloxacin Tablets Due to Nitrosamine Contamination

Hikma Pharmaceuticals is recalling 20,335 bottles of Ciprofloxacin 750 mg tablets because N-nitroso-ciprofloxacin levels exceeded FDA limits.

The agency’s classification

FDA (Drugs): Class II

Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work

What this means for you

Our assessment, not the agency’s: severity 4/5 (Severe).

The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: The recall is classified as FDA Class II due to N-nitroso-ciprofloxacin levels exceeding FDA interim control limits. The source does not report any illnesses, injuries, or deaths.

Plain-English summary

Hikma Pharmaceuticals USA Inc. is recalling 20,335 bottles of Ciprofloxacin Tablets, USP, 750 mg. The affected product is distributed nationwide in the United States. The recall involves three specific lots: CA083A, CA084A, and CA085A, all with an expiration date of 12/31/2026. The product is identified by NDC 0143-9929-50.

The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. Specifically, testing revealed that N-nitroso-ciprofloxacin results were above the FDA recommended interim control limit. N-nitrosamines are potential carcinogens that are strictly regulated in pharmaceutical products.

Consumers who have purchased these specific lots should stop using the medication and contact their healthcare provider for guidance on alternative treatment. The source text does not report any illnesses, injuries, or deaths associated with this recall.

The recalled product

Product
CIPROFLOXACIN (CIPROFLOXACIN)
Brand
CIPROFLOXACIN
Affected units
20,335

Distribution

Distributed nationwide across the United States.

Similar recalls